Background Nivolumab, an immune checkpoint inhibitor, is now a standard treatment for
previously treated advanced non–small-cell lung cancer based on the results from phase III …

Background Nivolumab (BMS-936558/ONO-4538) was the first monoclonal antibody
targeting programmed death (PD)-1. So far, a number of clinical trials on nivolumab have …

Objectives Nivolumab has recently received regulatory approval as a 2nd-line treatment of
non-small cell lung cancer (NSCLC). The data regarding its effectiveness and safety in real …

Introduction Nivolumab has been shown to be effective and safe in previously treated
patients with advanced non-small cell lung cancer (NSCLC). However, little is known …

Objectives To describe the treatment patterns and determine the effectiveness and safety of
nivolumab treatment for non-small cell lung cancer (NSCLC) in real-world setting in Japan …

Objective Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint
inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer …

Background CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced
non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS) …

Background Nivolumab has shown improved survival in the treatment of advanced non-
small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the …

Objectives Immune checkpoint inhibitors have become the standard of care for metastatic
non–small-cell lung cancer (NSCLC) progressing during or after platinum-based …

Nivolumab, a fully human immunoglobulin monoclonal antibody inhibiting the programmed
cell death protein‐1 receptor, demonstrated robust efficacy and a manageable safety profile …